Imported Cosmetic Creams from Pakistan and Middle Eastern Supply Chains: A Case-Cum-Research Study on Risks to Indian Health

 

Imported Cosmetic Creams from Pakistan and Middle Eastern Supply Chains: A Case-Cum-Research Study on Risks to Indian Health

Abstract

Imported skin-lightening, fairness, pain-relief and dermatological creams are increasingly available to Indian consumers through informal traders, social-media sellers, e-commerce platforms and cross-border personal imports. Some products marketed as ordinary cosmetics may contain undeclared corticosteroids, mercury, lead, arsenic, hydroquinone or other pharmacologically active substances. The source material emphasizes that the risk concerns specific products, batches and supply chains that fail safety, registration or labelling requirements—not all Pakistani, Middle Eastern or foreign cosmetics.

This case-cum-research paper examines the public-health and supply-chain risks associated with unsafe imported creams, with particular attention to Pakistani-origin products and products entering India through Middle Eastern commercial networks. It integrates a case-study approach with a proposed empirical research framework involving consumers, retailers, laboratories and regulatory stakeholders. The study examines product non-compliance, purchase channels, labelling deficiencies, duration of use and adverse health effects.

Because the supplied source is primarily a qualitative and regulatory case study rather than an actual consumer survey, the statistical tables below are explicitly presented as an illustrative empirical-analysis framework, not as claimed field results. The proposed analysis uses descriptive statistics, cross-tabulation, Chi-square tests and logistic regression. Illustrative Chi-square calculations demonstrate how hypotheses could be tested once actual field data are collected.

Keywords: imported cosmetics, skin-lightening creams, Pakistan, Middle East, mercury, lead, corticosteroids, consumer safety, India, cosmetics regulation, e-commerce, supply chain.

 

1. Introduction

Cosmetic creams are extensively used in India for skin lightening, pigmentation, acne, anti-ageing, dermatological and pain-relief purposes. Imported products can reach consumers through formal importers as well as travellers, informal retailers, social-media sellers, e-commerce platforms and cross-border resellers.

The central concern is the possibility that a product sold as an ordinary cosmetic may contain an undeclared pharmaceutical or toxic ingredient. The supplied source identifies mercury, lead, arsenic, corticosteroids, hydroquinone and other active substances as potential hazards.

The World Health Organization identifies mercury-containing skin-lightening products as a preventable source of mercury exposure and associates mercury exposure with kidney and nervous-system damage and risks to fetal development.

India's Cosmetics Rules, 2020 provide an important regulatory framework for imported cosmetics, including registration requirements and a general limit of 1 ppm for unintentional mercury in finished cosmetics, subject to the specified eye-area exception.

Therefore, the research problem is not simply whether a cosmetic originates from Pakistan or another foreign country. Rather, it concerns the interaction among:

Product formulation → importation → distribution → consumer purchase → prolonged exposure → health effects → regulatory response.

 

2. Background and Problem Statement

The supplied case material identifies five major stages of risk:

Product formulation and undeclared ingredients.

Importation and distribution.

Consumer exposure.

Health effects and adverse events.

Regulatory response and institutional gaps.

The problem becomes more complicated when products move through fragmented supply chains. Informal sellers may have limited knowledge of the contents of a product, while consumers may interpret foreign packaging, "herbal" claims or rapid cosmetic effects as indicators of quality.

Online commerce can further complicate traceability because sellers, listings and advertisements may change rapidly.

The study therefore treats unsafe imported cosmetics as both a public-health problem and a supply-chain governance problem.

 

3. Case Background: Pakistani-Origin and Foreign-Supplied Creams

The source material reports an Indian case concerning Pakistani-origin beauty creams in Maharashtra, including products identified in public reports as Goree Beauty Cream, Face Fresh Gold Beauty Cream and Golden Star Beauty Cream. The reported concern involved excessive mercury and lead and serious kidney problems among some women who had used such products. However, the source correctly emphasizes that product-specific clinical causation must be established through appropriate laboratory and medical investigation.

The case illustrates several risk indicators:

Risk indicator	Possible implication
Missing importer information	Weak traceability
Missing batch number	Difficult product recall
Missing expiry information	Unknown product age
Informal purchase	Reduced regulatory visibility
Online purchase	Difficult seller verification
Long-term use	Greater potential exposure
Skin-lightening claims	Possible repeated use
Lack of ingredient transparency	Consumer unable to assess risk

The case should therefore be interpreted as a serious safety signal, rather than evidence that all Pakistani cosmetics are unsafe.

 

4. Comparative Regulatory Case: Undeclared Corticosteroids

A second case described in the source involves a January 2026 regulatory alert concerning Eventone-C Cream and LUFA Advanced Pain Relief Gel. Laboratory analysis reportedly identified hydrocortisone and betamethasone respectively, although the products were presented without appropriate declaration or authorization.

This is important because the imported-cosmetic problem extends beyond heavy metals.

Potential hazards include:

corticosteroids;

antibiotics;

antifungal medicines;

hydroquinone;

retinoids;

local anaesthetics;

unsafe preservatives; and

contaminated or counterfeit ingredients.

Thus, regulatory inspection should examine chemical composition, rather than relying only on packaging or country of origin.

 

5. Objectives of the Study

The study has the following objectives:

To examine health risks associated with unsafe imported cosmetic creams.

To identify the major hazardous substances potentially present in imported creams.

To examine the relationship between purchase channel and product non-compliance.

To examine whether prolonged use is associated with a higher incidence of reported adverse effects.

To analyse consumer awareness of cosmetic-safety risks.

To examine the Indian regulatory framework governing imported cosmetics.

To develop an empirical statistical framework for measuring consumer exposure and risk.

To recommend measures for improving import surveillance, laboratory testing, e-commerce accountability and consumer protection.

 

6. Research Questions

RQ1

Does the purchase channel influence the probability of purchasing a product with labelling or compliance deficiencies?

RQ2

Is informal or online purchasing associated with greater reporting of adverse effects?

RQ3

Is duration of cosmetic use associated with adverse health effects?

RQ4

Does consumer awareness reduce the probability of purchasing potentially non-compliant products?

RQ5

Can regulatory and supply-chain characteristics predict the risk of adverse outcomes?

 

7. Hypotheses

H01

There is no significant association between purchase channel and cosmetic-product compliance.

H11

There is a significant association between purchase channel and cosmetic-product compliance.

H02

There is no significant association between informal purchase and reported adverse effects.

H12

There is a significant association between informal purchase and reported adverse effects.

H03

There is no significant association between duration of use and reported adverse effects.

H13

There is a significant association between duration of use and reported adverse effects.

H04

Consumer awareness has no significant association with safe purchasing behaviour.

H14

Consumer awareness has a significant association with safe purchasing behaviour.

 

8. Conceptual Framework

The proposed conceptual model is:

Supply-chain risk

↓

Product non-registration / incomplete labelling / adulteration

↓

Consumer purchase channel

↓

Frequency and duration of use

↓

Exposure to hazardous ingredients

↓

Adverse health effects

↓

Medical detection and regulatory intervention

Consumer awareness, enforcement intensity and laboratory testing act as moderating/control factors.

 

9. Methodology

9.1 Research Design

The supplied study is primarily qualitative and case-study based. It explicitly describes itself as an exploratory policy study rather than a clinical epidemiological investigation.

For an empirical extension, a mixed-method research design is recommended.

Phase I — Product study

Testing imported creams for:

mercury;

lead;

arsenic;

hydroquinone;

corticosteroids;

antibiotics;

antifungals;

microbial contamination;

pH and preservative compliance.

Phase II — Consumer survey

A sample of approximately 300–500 consumers may be selected.

Phase III — Key-informant interviews

Participants may include:

drug inspectors;

dermatologists;

nephrologists;

customs officers;

online sellers;

laboratory professionals;

consumer-rights representatives.

The source proposes a retail sample of 100–200 imported creams and a consumer sample of 300–500 users.

 

10. Variables

Variable	Measurement
Country of manufacture	Pakistan / Middle East / Other
Purchase channel	Pharmacy / retailer / online / informal
Registration	Yes / No / Unknown
Ingredient list	Complete / incomplete
Batch information	Available / unavailable
Expiry date	Available / unavailable
Duration of use	Months
Frequency	Daily / weekly / occasional
Awareness	Low / medium / high
Skin symptoms	Yes / No
Kidney-related symptoms	Yes / No
Neurological symptoms	Yes / No
Medical confirmation	Yes / No
Laboratory confirmation	Yes / No

These variables are consistent with the research design proposed in the source material.

---

11. Sampling Plan for an Empirical Study

A possible Indian study may use:

Respondent / unit	Proposed sample
Consumers	300
Retail outlets	100
Imported cream samples	150
Dermatologists	20
Drug inspectors/regulatory officials	10
Laboratory experts	10
Total indicative units	590

The consumer component should preferably use stratified sampling across formal and informal purchase channels rather than relying exclusively on convenience sampling.

 

12. Descriptive Statistical Analysis

For actual data, the first stage should calculate:

frequency;

percentage;

mean;

standard deviation;

minimum;

maximum.

Table 1. Illustrative Consumer Profile

The following figures are an illustrative analytical dataset created to demonstrate the statistical procedure. They are not reported field findings.

Variable	Category	Illustrative n	%
Gender	Female	180	60.0
	Male	120	40.0
Age	18–30	105	35.0
	31–45	120	40.0
	46+	75	25.0
Purchase	Formal	150	50.0
	Informal/online	150	50.0
Use duration	≤12 months	150	50.0
	>12 months	150	50.0

 

13. Product-Compliance Analysis

Table 2. Illustrative Product Compliance Classification

Compliance indicator	Compliant	Deficient	Total
Manufacturer information	105	45	150
Importer information	100	50	150
Batch number	112	38	150
Expiry information	115	35	150
Ingredient list	110	40	150
Registration information	98	52	150

The table demonstrates an important research principle: different forms of non-compliance should be measured separately rather than combining all deficiencies into one unexplained score.

 

14. Statistical Test 1: Purchase Channel and Product Deficiency

Hypothesis

H01: Purchase channel and product-label deficiency are independent.

Illustrative cross-tabulation

Purchase channel	Deficient label	Adequate label	Total
Informal/online	95	55	150
Formal	35	115	150
Total	130	170	300

Chi-square test

Calculated:

χ² = 48.869

df = 1

p < 0.001

Decision

Since p < 0.05, H01 would be rejected for this illustrative dataset.

Interpretation

The illustrative analysis indicates a statistically significant association between purchase channel and label deficiency. Informal/online purchases show a substantially larger proportion of deficient labels.

Important: This is an example of how the test should be reported. It is not evidence that the actual population has this exact relationship until real survey/product data are collected.

 

15. Statistical Test 2: Purchase Channel and Adverse Effects

Table 3. Illustrative Cross-tabulation

Purchase channel	Reported adverse effect	No adverse effect	Total
Informal/online	72	78	150
Formal	42	108	150
Total	114	186	300

Chi-square result

χ² = 12.733

df = 1

p = 0.00036

Decision

p < 0.05 → Reject H02 for the illustrative dataset.

Interpretation

The illustrative figures show a statistically significant association between informal/online purchase and reported adverse effects.

However, association does not establish causation. A product-specific causal conclusion would require laboratory confirmation, medical assessment and exposure history, as emphasized in the source.

 

16. Statistical Test 3: Duration of Use and Adverse Effects

Table 4. Illustrative Analysis

Duration of use	Adverse effect	No adverse effect	Total
>12 months	85	65	150
≤12 months	40	110	150
Total	125	175	300

Chi-square result

χ² = 27.771

df = 1

p < 0.001

Decision

Reject H03 for the illustrative dataset.

Interpretation

The illustrative results indicate a significant relationship between longer duration of use and reported adverse effects.

This relationship would be biologically and epidemiologically important to investigate in a genuine longitudinal or well-designed cross-sectional study.

 

17. Effect Size: Odds Ratio

Chi-square significance should be supplemented by an effect-size measure.

For the illustrative duration analysis:

[
OR=\frac{85/65}{40/110}
]

[
OR\approx3.60
]

Thus, in the illustrative dataset, consumers reporting more than 12 months of use have approximately 3.6 times the odds of reporting an adverse effect compared with those reporting 12 months or less.

Again, this is an illustrative calculation, not an estimate of the actual Indian population.

 

18. Logistic Regression Model

A stronger empirical study should use binary logistic regression.

Dependent variable

Adverse effect

1 = Yes

0 = No

Independent variables

duration of use;

purchase channel;

label deficiency;

registration status;

ingredient-risk category;

consumer awareness;

age;

frequency of application.

The model may be expressed as:

[
\log\left(\frac{P}{1-P}\right)

\beta_0+
\beta_1D+
\beta_2C+
\beta_3L+
\beta_4R+
\beta_5A+
\beta_6X
]

Where:

(P) = probability of adverse effect;

(D) = duration of use;

(C) = purchase channel;

(L) = labelling deficiency;

(R) = registration/product-risk status;

(A) = awareness;

(X) = demographic control variables.

The source itself recommends logistic regression for examining predictors of adverse effects.

 

19. Regression Analysis Table

Table 5. Recommended Logistic Regression Reporting Format

Predictor	B	S.E.	Wald	p-value	Odds Ratio
Informal/online purchase	—	—	—	—	—
>12 months use	—	—	—	—	—
Label deficiency	—	—	—	—	—
Unregistered product	—	—	—	—	—
Low awareness	—	—	—	—	—
Daily application	—	—	—	—	—
Age	—	—	—	—	—

Note: Actual coefficients should only be inserted after collecting and analysing real observations.

 

20. Reliability Test

If a multi-item consumer-awareness scale is used, internal consistency should be assessed using Cronbach's alpha.

For example, awareness may be measured using statements such as:

I check the manufacturer's name.

I check the importer information.

I check the ingredient list.

I check the batch number.

I check the expiry date.

I check whether the product is registered.

I understand that "herbal" does not necessarily mean safe.

A Cronbach's alpha of approximately 0.70 or higher is commonly treated as acceptable for exploratory research, subject to the scale's context and dimensionality.

 

21. ANOVA Analysis

If respondents are classified into three awareness groups—low, medium and high—ANOVA can examine whether mean safety scores differ.

Table 6. ANOVA Reporting Format

Source	Sum of Squares	df	Mean Square	F	Sig.
Between groups	—	2	—	—	—
Within groups	—	297	—
Total	—	299

Interpretation rule

If:

p < 0.05

there is evidence that at least one awareness group differs significantly from another.

A post-hoc test such as Tukey HSD should then identify which groups differ.

 

22. Risk-Classification Matrix

Table 7. Proposed Imported-Cream Risk Matrix

Risk characteristic	Low	Medium	High
Registration	Verified	Unclear	Absent
Labelling	Complete	Minor deficiency	Major deficiency
Batch information	Complete	Partial	Missing
Manufacturer	Verifiable	Difficult to verify	Unknown
Purchase channel	Formal	Marketplace	Informal/social media
Laboratory result	Compliant	Not tested	Hazard detected
Health claims	Cosmetic	Aggressive	Medical guarantee
Price	Normal	Unusually low	Extremely low

Products exhibiting multiple high-risk indicators should receive priority for regulatory sampling.

 

23. Health-Risk Framework

Substance/problem	Short-term effects	Potential long-term effects
Mercury	Irritation, rash, burning	Kidney and neurological effects
Lead	Often limited visible symptoms	Neurodevelopmental, kidney and reproductive effects
Arsenic	Irritation and gastrointestinal effects	Neurological, cardiovascular and cancer risks
Potent corticosteroids	Temporary reduction in inflammation	Skin thinning, acne, infections and pigmentation problems
Hydroquinone/related agents	Dryness and irritation	Pigmentation disorders and dermatitis
Unlabelled antibiotics/antifungals	Temporary symptom improvement	Allergy, resistance and treatment failure
Counterfeit/contaminated products	Variable skin reactions	Infection, chemical injury and organ toxicity

The source specifically identifies these categories of potential effects.

 

24. Indian Regulatory Framework

India's Cosmetics Rules, 2020 provide important controls over imported cosmetics.

Major regulatory requirements

1. Registration before import

Imported cosmetics require registration by the Central Licensing Authority.

2. Mercury control

Unintentional mercury in finished cosmetics is generally limited to 1 ppm, subject to the specified exception.

3. Import-point examination

Authorities can examine and sample consignments where violations are suspected and hold products pending laboratory analysis.

4. Multi-agency enforcement

Effective control requires coordination among CDSCO, state drug-control authorities, Customs, laboratories, e-commerce platforms, police/cybercrime authorities, hospitals and consumer-protection agencies.

 

25. Supply-Chain Analysis

Figure 1. Risk Transmission Model

Foreign Manufacturer

↓

Exporter / Trading Company

↓

Middle-Eastern Re-export / Transit Network

↓

Importer / Informal Distributor

↓

Retailer / Social Media / E-commerce Seller

↓

Indian Consumer

↓

Repeated Cosmetic Application

↓

Potential Exposure

↓

Health Effect

↓

Medical Detection

↓

Regulatory Investigation

The critical intervention points are:

border inspection;

importer verification;

laboratory testing;

online listing verification;

retail inspection;

adverse-event reporting.

 

26. Key Findings

The case analysis indicates seven major findings.

Finding 1: Risk is product-specific

The evidence does not support treating all Pakistani or Middle Eastern cosmetics as unsafe. The source explicitly cautions against country-wide generalisation.

Finding 2: Cosmetic and medicine boundaries can become blurred

A product may be presented as a cosmetic while containing pharmacologically active ingredients.

Finding 3: Heavy metals can remain invisible

Consumers cannot reliably identify mercury or lead contamination from appearance, smell or texture.

Finding 4: Informal digital channels increase traceability problems

Social-media sellers and online resellers can make product identification and regulatory enforcement more difficult.

Finding 5: Long-term exposure requires particular attention

The proposed empirical design should record duration and frequency of use rather than merely asking whether a person has ever used a product.

Finding 6: Labelling is an important first-line control

Missing manufacturer, importer, batch, expiry or ingredient information should be treated as warning signals.

Finding 7: Statistical association cannot replace clinical evidence

A statistical association between product use and illness should trigger investigation, but should not automatically be interpreted as proof of causation.

 

27. Policy Recommendations

27.1 Strengthen import surveillance

Risk-based testing of skin-lightening, anti-acne and pain-relief creams.

Random testing for mercury, lead and arsenic.

Screening for undeclared corticosteroids and hydroquinone.

Greater Customs-CDSCO coordination.

Public database of registered imported cosmetics.

These measures are consistent with the recommendations in the supplied source.

27.2 Control online sales

E-commerce and social-media platforms should:

verify sellers;

verify importer/manufacturer information;

remove unregistered products;

retain transaction records;

monitor exaggerated whitening and medical claims;

cooperate with regulators.

27.3 Strengthen laboratory capacity

Testing infrastructure should include capabilities such as:

atomic absorption spectroscopy;

ICP-MS;

HPLC;

corticosteroid screening;

microbial testing;

packaging and label verification.

27.4 Develop adverse-event reporting

A national reporting system should capture:

product name;

manufacturer;

batch number;

seller;

purchase channel;

duration of use;

symptoms;

medical diagnosis;

laboratory findings.

 

28. Consumer Protection Framework

Consumers should be advised to:

Verify manufacturer details.

Check importer information.

Check batch number.

Check expiry date.

Read the complete ingredient list.

Avoid products promising instant or guaranteed whitening.

Avoid products with no traceable seller.

Avoid indefinite use of medicated creams without professional advice.

Be particularly cautious when products are intended for children or pregnancy.

Report suspected adverse reactions.

The source specifically warns that "herbal" or "natural" claims do not automatically establish safety.

 

29. Research Limitations

This study has several limitations.

29.1 No original clinical dataset

The supplied material is primarily a case and regulatory analysis. Therefore, the statistical tables in this paper are illustrative.

29.2 No batch-level causal evidence

A causal claim requires:

Product laboratory confirmation + medical diagnosis + exposure history + appropriate biomonitoring where required.

29.3 Possible reporting bias

Consumers with adverse reactions may be more likely to report problems than consumers without symptoms.

29.4 Selection bias

Online and informal consumers may be difficult to sample systematically.

29.5 Country-of-origin limitation

Country of manufacture should never be treated as an independent proof of product danger.

 

30. Managerial and Institutional Implications

For regulators

The emphasis should move from reactive seizure to risk-based preventive surveillance.

For e-commerce companies

Product-registration and importer-verification systems should become integral to marketplace governance.

For manufacturers

Complete ingredient disclosure and batch traceability are essential.

For hospitals

Clinicians should consider cosmetic exposure when unexplained dermatological, renal or neurological symptoms occur.

For consumers

Price, foreign origin, attractive packaging or "herbal" claims should not be treated as substitutes for safety verification.

 

31. Conclusion

Imported cosmetic creams represent an important intersection of consumer behaviour, international trade, supply-chain management, public health and regulatory governance.

The case evidence demonstrates that risks may arise from undeclared corticosteroids, heavy metals, counterfeit products, incomplete labelling and weak traceability. The reported Pakistani-origin cases provide an important safety signal, while the regulatory example involving undeclared corticosteroids demonstrates that the problem is broader than mercury contamination alone.

India already possesses a regulatory foundation through the Cosmetics Rules, 2020, including registration requirements for imported cosmetics and controls concerning mercury.

The major challenge is implementation across fragmented physical and digital supply chains.

The proposed empirical framework demonstrates how Chi-square, odds ratios, reliability analysis, ANOVA and logistic regression can be incorporated into a full research study. The illustrative statistical results suggest potentially important relationships between informal purchasing, product deficiencies, duration of use and reported adverse effects, but these figures must not be interpreted as actual field findings.

The central policy conclusion is therefore:

India should regulate the product, batch, importer and supply chain on the basis of evidence—not judge safety solely by country of origin.

A coordinated system combining Customs surveillance, CDSCO/state enforcement, laboratory testing, e-commerce monitoring, medical reporting and consumer education can substantially strengthen protection against unsafe imported cosmetics.

 

References

World Health Organization. Mercury and Health. WHO. The supplied source identifies WHO evidence linking mercury exposure with kidney, neurological, skin and developmental risks.

Central Drugs Standard Control Organisation (CDSCO). Cosmetics Rules, 2020. Government of India. The source identifies registration requirements, mercury limits and import inspection provisions.

Drug Regulatory Authority of Pakistan (DRAP). Rapid Alert: Eventone-C Creams and LUFA Advanced Pain Relief Gel Containing Unauthorized Pharmaceutical Ingredients. The source reports laboratory identification of hydrocortisone and betamethasone.

Supplied case material. Imported Cosmetic Creams from Pakistan and Middle Eastern Supply Chains: A Case-Based Research Paper on Risks to Indian Health. User-provided source document.

Revised Appendices — Analytical Form

Appendix A: Analysis of Imported Cosmetic Product Risk

The case evidence indicates that the principal risk is associated with product-level non-compliance rather than country of origin. The risk becomes higher when several characteristics occur simultaneously: incomplete labelling, absence of importer details, missing batch information, unverified sellers, informal distribution and possible undeclared pharmaceutical or toxic ingredients.

Risk factor	Analytical observation	Risk implication
Unregistered product	Product cannot be readily verified through the formal regulatory system	High
Missing manufacturer	Supply-chain traceability is weakened	High
Missing importer	Indian accountability becomes difficult	High
Missing batch number	Recall and laboratory tracing become difficult	High
Missing expiry date	Product age and safety cannot be established	Medium–High
Incomplete ingredients	Consumer cannot identify active substances	High
Informal seller	Regulatory visibility is limited	High
Social-media seller	Seller identity/listing may change rapidly	High
Unusually rapid whitening effect	May indicate potent active ingredient	Requires laboratory investigation
Long-term use	Increases cumulative exposure concern	High
Laboratory-confirmed hazardous substance	Direct product safety concern	Very high

Analysis: The greatest concern arises when several risk factors are present together. Therefore, regulatory agencies should use a cumulative risk approach instead of treating any single indicator as conclusive proof of danger.

 

Appendix B: Analytical Comparison of Formal and Informal Supply Channels

Dimension	Formal channel	Informal/online channel	Analytical implication
Importer identification	Usually available	May be incomplete	Traceability gap
Product documentation	More likely to be available	May be absent	Verification difficulty
Registration	More readily verifiable	May be unknown	Regulatory risk
Seller identity	Relatively stable	Can change	Enforcement difficulty
Consumer information	Usually structured	May be promotional	Information asymmetry
Product recall	More feasible	More difficult	Higher enforcement cost
Laboratory testing	More accessible to authorities	Requires targeted sampling	Surveillance challenge
Consumer complaint tracking	Relatively easier	Fragmented	Reporting gap

The source identifies informal shops, passenger-baggage channels, social-media advertisements, online marketplaces, Middle-Eastern resellers and repackaged products as possible routes through which products may reach consumers.

Analytical conclusion

The supply-chain problem is therefore one of traceability asymmetry. Formal channels create identifiable points of accountability, whereas fragmented informal channels create multiple points at which product identity, composition and ownership can become difficult to establish.

 

Appendix C: Analysis of Health Risks by Hazard

Hazard	Immediate/visible effect	Potential systemic effect	Analytical risk level
Mercury	Irritation, rash, pigmentation changes	Kidney and neurological effects	Very high
Lead	Often limited visible symptoms	Neurological, kidney and reproductive effects	High
Arsenic	Irritation, gastrointestinal effects	Neurological, cardiovascular and cancer risks	High
Corticosteroids	Temporary reduction of inflammation	Skin thinning, infections, pigmentation disorders	High
Hydroquinone/related bleaching agents	Dryness, irritation	Severe pigmentation disorders/dermatitis	Medium–High
Unlabelled antibiotics/antifungals	Temporary improvement	Allergy, resistance and treatment failure	Medium–High
Counterfeit/contaminated products	Variable reactions	Infection, chemical injury and organ toxicity	Very high

The source specifically identifies mercury, lead, arsenic, potent corticosteroids, hydroquinone-related agents and unlabelled pharmaceutical ingredients as important categories for investigation.

Analytical conclusion

The health-risk pattern is multidimensional. A product may create dermatological risk, systemic toxicity, or both. Consequently, research should not use "skin reaction" as the only dependent variable; kidney, neurological and reproductive indicators should also be investigated where medically appropriate.

 

Appendix D: Chi-Square Analysis of Purchase Channel and Product Deficiency

Observed Data

Purchase channel	Deficient label	Adequate label	Total
Informal/online	95	55	150
Formal	35	115	150
Total	130	170	300

Expected frequencies

For example:

[
E_{11}=\frac{150\times130}{300}=65
]

The corresponding expected table is:

Purchase channel	Deficient expected	Adequate expected
Informal/online	65	85
Formal	65	85

Test result

[
\chi^2=48.869
]

[
df=1
]

[
p<0.001
]

Analysis

Because p < 0.05, the null hypothesis of independence is rejected for this illustrative dataset.

The analysis indicates a statistically significant relationship between purchase channel and label deficiency.

The proportion of deficient labels is:

Informal/online = 95/150 = 63.3%

Formal = 35/150 = 23.3%

Thus, the illustrative difference is approximately 40 percentage points.

Interpretation

This suggests that informal and online channels deserve greater regulatory surveillance. However, the figures are illustrative and must not be reported as actual field observations.

 

Appendix E: Chi-Square Analysis of Purchase Channel and Adverse Effects

Observed Data

Purchase channel	Adverse effect	No adverse effect	Total
Informal/online	72	78	150
Formal	42	108	150
Total	114	186	300

Test result

[
\chi^2=12.733
]

[
df=1
]

[
p<0.001
]

Analysis

The illustrative result is statistically significant at the 5% level.

Adverse-effect reporting is:

Informal/online = 48.0%

Formal = 28.0%

The difference is:

[
48.0-28.0=20.0%
]

Interpretation

The illustrative analysis indicates that respondents purchasing through informal/online channels report adverse effects more frequently.

However, this does not establish that the purchase channel caused the health effect. Confounding variables such as duration of use, product composition, frequency of application and pre-existing health conditions must be examined.

 

Appendix F: Analysis of Duration of Use and Adverse Effects

Observed Data

Duration of use	Adverse effect	No adverse effect	Total
More than 12 months	85	65	150
12 months or less	40	110	150
Total	125	175	300

Test result

[
\chi^2=27.771
]

[
df=1
]

[
p<0.001
]

Percentage analysis

Duration	Adverse-effect rate
>12 months	56.7%
≤12 months	26.7%

Difference:

[
56.7-26.7=30.0\text{ percentage points}
]

Odds Ratio

[
OR=\frac{85\times110}{65\times40}
]

[
OR\approx3.60
]

Interpretation

The illustrative odds ratio suggests that the odds of reporting an adverse effect are approximately 3.6 times higher among respondents reporting more than 12 months of use.

This provides a stronger interpretation than Chi-square alone because it measures the magnitude of association.

 

Appendix G: Comparative Statistical Interpretation

Variable	Group 1	Group 2	Difference	Statistical result	Interpretation
Label deficiency	Informal/online 63.3%	Formal 23.3%	40.0 pp	χ²=48.869, p<0.001	Significant association
Adverse effects	Informal/online 48.0%	Formal 28.0%	20.0 pp	χ²=12.733, p<0.001	Significant association
Adverse effects	>12 months 56.7%	≤12 months 26.7%	30.0 pp	χ²=27.771, p<0.001	Significant association
Odds of adverse effect	>12 months	≤12 months	OR=3.60	—	Higher odds in long-duration group

Overall analytical conclusion: In the illustrative dataset, all three relationships are statistically significant. The strongest apparent association concerns duration of use and adverse effects, followed by purchase channel and product-label deficiency.

 

Appendix H: Logistic Regression Analysis Framework

The binary dependent variable is:

[
Y=
\begin{cases}
1 & \text{Adverse effect reported}\
0 & \text{No adverse effect}
\end{cases}
]

The proposed explanatory variables are:

Variable	Coding
Informal/online purchase	1 = Yes, 0 = No
Duration >12 months	1 = Yes, 0 = No
Label deficiency	1 = Yes, 0 = No
Unregistered product	1 = Yes, 0 = No
Daily use	1 = Yes, 0 = No
Low awareness	1 = Yes, 0 = No
Age	Continuous
Frequency of application	Continuous/ordinal

The estimated model would be:

[
\ln\left(\frac{P}{1-P}\right)

\beta_0+\beta_1C+\beta_2D+\beta_3L+\beta_4R+\beta_5F+\beta_6A+\epsilon
]

where (P) represents the probability of an adverse effect.

Analytical interpretation

The logistic model is preferable to relying exclusively on Chi-square because several risk factors can be examined simultaneously. It can determine whether duration of use remains associated with adverse effects after controlling for purchase channel, age, awareness and other variables.

 

Appendix I: Regulatory Gap Analysis

Regulatory control	Intended protection	Potential weakness identified by case	Required analytical response
Import registration	Establish legal identity	Informal entry can bypass visibility	Risk-based border surveillance
Ingredient declaration	Inform consumers	Undeclared pharmaceutical ingredients	Laboratory verification
Batch information	Enable recall	Missing batch data	Mandatory traceability
Importer information	Establish accountability	Informal sellers may obscure source	Seller/importer verification
Laboratory testing	Detect hazardous substances	Sampling resources are finite	Risk-based prioritisation
E-commerce controls	Prevent online distribution	Seller/listing turnover	Platform-level monitoring
Adverse-event reporting	Detect health signals	Under-reporting	Simple national reporting system

India's regulatory framework includes imported-cosmetic registration, mercury limits and examination/sampling provisions.

 

Appendix J: Integrated Risk Score Analysis

An analytical risk score can be constructed for research purposes using observed indicators.

Indicator	Score
No registration evidence	2
Missing manufacturer	2
Missing importer	2
Missing batch number	1
Missing expiry date	1
Incomplete ingredient list	2
Informal seller	2
Social-media seller	2
Unverified medical claim	2
Laboratory-confirmed hazardous ingredient	4

Interpretation

Total score	Risk classification
0–4	Low
5–8	Moderate
9–13	High
14+	Critical

This score should be treated as a research classification instrument, not as an official Government of India risk standard.

Analytical value

The score allows researchers to compare products systematically and identify products requiring laboratory testing or regulatory investigation.

 

Appendix K: Integrated Findings Matrix

Research issue	Evidence examined	Statistical/analytical approach	Result
Product non-compliance	Labelling/registration indicators	Frequency and percentage	Major traceability concern
Purchase channel	Formal vs informal/online	Chi-square	Significant in illustrative data
Adverse effects	Reported symptoms	Chi-square	Significant in illustrative data
Duration of use	≤12 vs >12 months	Chi-square + OR	Significant in illustrative data
Magnitude of association	Long-term use	Odds ratio	OR ≈ 3.60
Multiple risk factors	Consumer/product characteristics	Logistic regression	Recommended
Consumer awareness	Safety scale	Reliability + ANOVA	Recommended
Product classification	Multiple risk indicators	Risk-score analysis	Enables prioritisation

 

Appendix L: Final Analytical Interpretation

The combined analysis supports the following research interpretation:

First, imported-cosmetic safety is primarily a traceability and product-compliance issue.

Second, informal and online distribution channels represent important points for regulatory attention because they can weaken the visibility of importer, manufacturer and batch information.

Third, prolonged use is an important variable that should be incorporated into empirical models rather than simply recording whether a consumer has ever used an imported cream.

Fourth, Chi-square testing can establish whether categorical variables are associated, while the odds ratio can indicate the magnitude of a two-group association.

Fifth, logistic regression should be used in the final empirical study to distinguish the independent contribution of purchase channel, duration, labelling deficiency, registration status, frequency of use and awareness.

Sixth, laboratory and clinical evidence remain essential. Statistical association alone cannot demonstrate that a particular cream caused kidney, neurological or other disease.

The source itself emphasizes that product-specific causal conclusions require laboratory testing, medical examination, exposure history and, where appropriate, biomonitoring.

Therefore, the final research model should move from simple description → association testing → effect-size estimation → multivariate analysis → laboratory/clinical confirmation.